NHI.no
Annonse
Informasjon

Seksuelle problemer i overgangsalderen

Seksuelle problemer er hyppige i overgangsalderen. Blant utfordringene er lystproblemer, opphisselsesproblemer, orgasmeproblemer og smerteproblemer.  Behandling velges ut i fra individuelle vurderinger.

Lystproblemer forekommer hos 40 til 55 prosent av kvinner etter overgangsalderen. Illustrasjonsfoto: Colourbox

Sist oppdatert:

2. feb. 2021

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Seksuell dysfunksjon i menopausen . Referanselisten for dette dokumentet vises nedenfor

  1. Gregersen N, Hilmand CB, Jensen PT, Giraldi AGE. Seksuel dysfunktion i menopausen. Ugeskr Læger 2006; 168: 559-63. PubMed
  2. Basson R, Berman J, Burnett A et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888-93. PubMed
  3. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001; 76: 456-60. PubMed
  4. Fugl-Meyer A, Fugl-Meyer KS. Sexual disabilities, problems and satisfaction in 18-74 year old swedes. Scand J Sexology 1999; 2: 79-106. PubMed
  5. Castelo-Branco C, Blumel JE, Araya H et al. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003; 23: 426-30. PubMed
  6. Köster A, Eplov LF, Garde K. Anticipations and experiences of menopause in a Danish female general population cohorte born in 1936. Arch Womens Ment Health 2002; 5: 9-13. PubMed
  7. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004; 11: 120-30. PubMed
  8. Avis NE, Stellato R, Crawford S et al. Is there an association between menopause status and sexual functioning? Menopause 2000; 7: 297-309. PubMed
  9. Shufelt CL, Johnson BD, Berga SL, et al. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause 2011; 18:943. PubMed
  10. Martin KA, Rosenson RS. Menopausal hormone therapy and cardiovascular risk. UpToDate, last updated Apr 18, 2019. UpToDate
  11. Bachmann G, Bancroft J, Braunstein G et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-5. PubMed
  12. Huang G, Basaria S, Travison TG, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause 2014; 21:612. PubMed
  13. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839. New England Journal of Medicine
  14. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD001500. Cochrane (DOI)
  15. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009; 16: 719-27. PubMed
  16. Shifren JL, Davis SR. Androgens in postmenopausal women: a review. Menopause 2017; 24:970. PubMed
  17. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-8. New England Journal of Medicine
  18. Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008; 5:646. PubMed
  19. Dennerstein L, Lehert P. Modeling mid-aged women's sexual functioning: a prospective, population-based study. J Sex Marital Ther 2004; 30: 173-83. PubMed
Annonse
Annonse